Skip to search formSkip to main contentSkip to account menu

Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine protocol

Known as: C-MOPP, CMOPP, Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine 
A chemotherapy combination consisting of cyclophosphamide, mechlorethamine, prednisone, procarbazine, and vincristine.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
C-MOPP is a chemotherapy regimen for the treatment of Non-Hodgkin lymphoma (NHL). Because rituximab improves results in B-cell… 
2008
2008
The article, “Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate… 
2007
2007
Median age was 37 years (15-84). Nodularsclerosis and mixed cellularity were equally expressed. Advanced stages (III & IV) were… 
Review
1996
Review
1996
Although bone marrow biopsy is considered the best procedure to detect bone marrow involvement by Hodgkin's disease (HD), in… 
1995
1995
BACKGROUND To carry out a study on the prognostic factors in large cell lymphomas (LCL) treated during the last decade and… 
1986
1986
Early in 1977, a new combination chemotherapy program was initiated at the New York Hospital-Cornell Medical Center for large… 
1983
1983
SummaryVindesine (desacetyl vinblastine amide sulfate, DVA) was used in combination with CCNU (lomustine) and melphalan (Alkeran… 
1981
1981
Recent progress in the chemotherapy of Non-Hodgkin's lymphomas has been achieved in the management of subtypes with unfavourable… 
1979
1979
Thirty‐nine untreated patients with either lymphocytic or nodular mixed/nodular histiocytic non‐Hodgkin's lymphoma, stage II‐IV…